Current stock page

Stock Analysis

Aurinia Pharmaceuticals Inc. (AUPH) Stock Analysis

Aurinia Pharmaceuticals Inc. (AUPH) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

AUPH Stock Analysis Summary

Aurinia Pharmaceuticals Inc. (AUPH) currently has an AIQ Score of 75/100, indicating a bullish setup. Value is the strongest factor at 84/100. Risk is the weakest current factor at 68/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

AUPH at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$15.73
AIQ Score75/100
Overall ViewBullish
Technical Analysis ConsensusStrong Sell
Market Cap$2.1B
P/E Ratio (TTM)6.64
Forward P/E—
EPS (Q3 FY2026)$0.24
Revenue (Q3 FY2026)$83.7M
Dividend Yield (TTM)0.00%
Beta0.64
Volume691.3K
52-week range$13.52-$19.25
RSI 1439.95
50-Day SMA$16.48
200-Day SMA$15.73
Analyst Price Target$18.00
Next EarningsFeb 25, 2027
As of Nov 13, 2026 · Market close

AUPHAurinia Pharmaceuticals Inc.

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$15.73−$0.48 (−2.96%)

Latest quote

  • Momentum
    73
  • Value
    84
  • Quality
    77
  • Risk resilience
    68
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

AUPH Stock Analysis Summary

Aurinia Pharmaceuticals Inc. (AUPH) currently has an AIQ Score of 75/100, indicating a bullish setup. Value is the strongest factor at 84/100. Risk resilience is the weakest current factor at 68/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bullish

In a bullish regime, AUPH has AIQ Score of 75/100 with Value base of 84/100 and fading Risk resilience at 68/100. Wait for component alignment before adding exposure.

Healthcare · -2.96% stock move · AUPH classified in Biotechnology.

Current Evidence

BullishAUPH is in a bullish AIQ regime; Value is the strongest visible factor at 84/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is AUPH Bullish or Bearish Right Now?

AUPH currently has a bullish overall setup. Value is the strongest factor at 84/100, while Risk Resilience is weakest at 68/100. The current evidence suggests a constructive setup.

Bull Case
  • - Quality is supportive at 77/100.
  • - Momentum is constructive at 73/100.
  • - Risk Resilience is supportive at 68/100.
  • - Analyst target implies +14.43% upside from the latest quote.
Bear Case
  • - Price is -0.00% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (34 vs 7).

Current Consensus

AUPH's Technical Analysis Consensus is currently Strong Sell, with 7 buy, 5 neutral, and 34 sell votes. AUPH's 14-day RSI is 39.95, which places the stock in a weaker momentum range. AUPH's beta is 0.64, indicating lower market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in AUPH?

The largest recent change in AUPH is Momentum moving down by 4.0 points over the available 7-day comparison window. Value remains the strongest visible factor.

AIQ Score
-1.0
Momentum
-4.0
Quality
+0.0
Risk
+0.0

What Would Change the AUPH Outlook?

The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

AUPH Decision Framework

Public evidence layers, setup checks, and risk context for Aurinia Pharmaceuticals Inc..

Aurinia Pharmaceuticals Inc. (AUPH) Stock Analysis

Aurinia Pharmaceuticals Inc. has an AIQ Score of 75/100 in a Bullish regime. Value is strongest at 84/100. Beta is 0.64, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextAUPH is in a Bullish AIQ regime with score 75/100.
Signal ConflictThe primary conflict is that value leads at 84/100 while risk lags at 68/100.
Factor EvidenceMomentum 73/100 · Value 84/100 · Quality 77/100 · Risk 68/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Value is the strongest factor at 84/100.

TimingPass

Momentum is 73/100 and RSI (14) is 39.9.

Regime fitPass

AUPH is in a Bullish regime at 75/100.

Risk controlPass

Risk factor is 68/100 with beta 0.64 and annual volatility 35.53%.

ConflictPass

Current conflict: value leads at 84/100 while risk lags at 68/100.

AIQ Score
75/100
Price
$15.73
Beta
0.64
RSI (14)
39.9

AUPH Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

AUPH Fundamentals

AUPH valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$83.7M
Net income
$31.7M
Free cash flow
$46.34M
View full AUPH fundamental analysis

AUPH Technical Analysis

AUPH technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
39.95
Price vs SMA-50
-4.55%
View full AUPH technical analysis

AUPH Stock Catalysts

Track AUPH earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 25, 2027
Analyst target
$18.00
News items
2
View AUPH earnings and stock catalysts

AUPH Dividend Analysis

AUPH dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View AUPH dividend history and analysis

AUPH Financial Data

AUPH revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$83.7M
EPS
$0.24
Periods
8
View AUPH financials

AUPH Risk Analysis

AUPH volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.64
Risk score
68/100
1Y volatility
35.52%
View AUPH risk analysis

AUPH Stock News

AUPH stock news, market tone, recent headlines, and catalyst context.

News items
2
Updated
Nov 15, 2026
Sentiment
—
Read AUPH stock news

AUPH vs Biotechnology Peers

Current peer cohort: AUPH · AVBP · AXSM · BBIO · BCRX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
AUPH
Current stock
75/10084/10073/10068/1000.1635.52%Current
AVBP
ArriVent BioPharma, Inc.
35/100—23/10032/100-0.0881.51%AUPH vs AVBP
AXSM
Axsome Therapeutics, Inc.
47/10065/10024/10057/1000.245.79%AUPH vs AXSM
BBIO
BridgeBio Pharma, Inc.
64/10055/10069/10062/1000.5544.14%AUPH vs BBIO
BCRX
BioCryst Pharmaceuticals, Inc.
59/10086/10042/10055/1000.3648.06%AUPH vs BCRX
Pairwise Compare links: AVBP · AXSM · BBIO · BCRXAUPH vs AVBPAUPH vs AXSMAUPH vs BBIOAUPH vs BCRXCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a AUPH stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for AUPH: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
6.64
As of Nov 13, 2026
Revenue growth
13.93%
Gross margin
90.73%
Current debt / equity
0.09
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$83.7M
Quarter net income
$31.7M
Quarter free cash flow
$46.34M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Bearish
RSI 14
39.95
MACD
-0.11

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
68/100
Beta
0.64
Annual volatility
35.52%
Max drawdown
-21.75%

AUPH Stock FAQ

What is AUPH stock price today?

Aurinia Pharmaceuticals Inc.'s current stock price is $15.73. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is AUPH bullish or bearish right now?

AUPH's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is AUPH's market cap?

AUPH's market cap is $2.1B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is AUPH's current P/E ratio?

AUPH's current P/E ratio is 6.64 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is AUPH's RSI?

AUPH's 14-day RSI is 39.95 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is AUPH above its 50-day and 200-day moving averages?

AUPH is -4.55% from its 50-day SMA and -0.00% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is AUPH's next earnings date?

AUPH's next earnings date is currently listed as Feb 25, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does AUPH pay a dividend?

AUPH's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.